Search

Author/Creator Diehl, Annette

1. Methotrexate withdrawal in patients with rheumatoid arthritis who achieve low disease activity with tofacitinib modified-release 11 mg once daily plus methotrexate (ORAL Shift): a randomised, phase 3b/4, non-inferiority trial. (September 2019)

Authors:
Cohen, Stanley B; Pope, Janet; Haraoui, Boulos; Irazoque-Palazuelos, Fedra; Korkosz, Mariusz; Diehl, Annette; Rivas, Jose L; Lukic, Tatjana; Liu, Shixue; Stockert, Lori; Iikuni, Noriko; Keystone, Edward C
Journal:
Lancet
Issue:
Volume 1:Number 1(2019)
Page Start:
e23
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. LB0004 METHOTREXATE WITHDRAWAL IN PATIENTS WITH RHEUMATOID ARTHRITIS WHO ACHIEVE LOW DISEASE ACTIVITY WITH TOFACITINIB MODIFIED-RELEASE 11 MG ONCE DAILY + METHOTREXATE: A RANDOMISED NON-INFERIORITY PHASE 3B/4 STUDY. (June 2019)

Authors:
B. Cohen, Stanley; Pope, Janet; Haraoui, Boulos; Irazoque-Palazuelos, Fedra; Korkosz, Mariusz; Diehl, Annette; Luis Rivas, Jose; Lukic, Tatjana; Liu, Shixue; Stockert, Lori; Iikuni, Noriko; Keystone, Edward
Journal:
Annals of the rheumatic diseases
Issue:
Volume 78(2019)Supplement 2
Page Start:
260
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial. Issue 3 (26th September 2016)

Authors:
Wallace, Daniel J; Strand, Vibeke; Merrill, Joan T; Popa, Serghei; Spindler, Alberto J; Eimon, Alicia; Petri, Michelle; Smolen, Josef S; Wajdula, Joseph; Christensen, Jared; Li, Cheryl; Diehl, Annette; Vincent, Michael S; Beebe, Jean; Healey, Paul; Sridharan, Sudhakar
Journal:
Annals of the rheumatic diseases
Issue:
Volume 76:Issue 3(2017)
Page Start:
534
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Efficacy and safety of tofacitinib modified-release 11 mg once daily plus methotrexate in adult patients with rheumatoid arthritis: 24-week open-label phase results from a phase 3b/4 methotrexate withdrawal non-inferiority study (ORAL Shift). Issue 2 (8th June 2021)

Authors:
Cohen, Stanley B; Pope, Janet; Haraoui, Boulos; Mysler, Eduardo; Diehl, Annette; Lukic, Tatjana; Liu, Shixue; Stockert, Lori; Germino, Rebecca; Menon, Sujatha; Shi, Harry; Keystone, Edward C
Journal:
RMD open
Issue:
Volume 7:Issue 2(2021)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Evaluation of the Effect of Abrocitinib on Drug Transporters by Integrated Use of Probe Drugs and Endogenous Biomarkers. Issue 3 (9th May 2022)

Authors:
Vourvahis, Manoli; Byon, Wonkyung; Chang, Cheng; Le, Vu; Diehl, Annette; Graham, Daniela; Tripathy, Sakambari; Raha, Nancy; Luo, Lina; Mathialagan, Sumathy; Dowty, Martin; Rodrigues, A. David; Malhotra, Bimal
Journal:
Clinical pharmacology & therapeutics
Issue:
Volume 112:Issue 3(2022)
Page Start:
665
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗